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Abstract
The conserved 11 zinc-finger protein CTCF is involved in several transcriptional mechanisms, including insulation and
enhancer blocking. We had previously identified two composite elements consisting of a CTCF and a TR binding site at the
chicken lysozyme and the human c-myc genes. Using these it has been demonstrated that thyroid hormone mediates the
relief of enhancer blocking even though CTCF remains bound to its binding site. Here we wished to determine whether
CTCF and TR combined sites are representative of a general feature of the genome, and whether such sites are functional in
regulating enhancer blocking. Genome wide analysis revealed that about 18% of the CTCF regions harbored at least one of
the four different palindromic or repeated sequence arrangements typical for the binding of TR homodimers or TR/RXR
heterodimers. Functional analysis of 10 different composite elements of thyroid hormone responsive genes was performed
using episomal constructs. The episomal system allowed recapitulating CTCF mediated enhancer blocking function to be
dependent on poly (ADP)-ribose modification and to mediate histone deacetylation. Furthermore, thyroid hormone
sensitive enhancer blocking could be shown for one of these new composite elements. Remarkably, not only did the
regulation of enhancer blocking require functional TR binding, but also the basal enhancer blocking activity of CTCF was
dependent on the binding of the unliganded TR. Thus, a number of composite CTCF/TR binding sites may represent a
subset of other modular CTCF composite sites, such as groups of multiple CTCF sites or of CTCF/Oct4, CTCF/Kaiso or CTCF/
Yy1 combinations.
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Introduction
The conserved 11 zinc-finger protein CTCF is involved inseveral
transcriptional mechanisms, such as gene activation [1], gene
repression [2,3] and enhancer blocking [4–13]. In vertebrates,
CTCF is the only identified protein that is able to bind to insulators
and to mediate enhancer blocking [4]. Insulators block the action of
enhancers when positioned between enhancer and promoter,
thereby preventing inappropriate action of enhancers on neigh-
bouring genes. The CTCF-mediated enhancer blocking can be
constitutive, for example in the locus control region of the b-globin
genes [4]. In other cases, regulation of enhancer blocking has been
described at the level of DNA-binding. It has been shown that
CTCF is not able to bind to those binding-sites that include
methylated CpGs. A well characterized system for such a regulation
is the imprinting control region (ICR) of the Igf2/H19 locus. At this
lCR the binding-site for CTCF on the paternal allele is methylated.
This leads to inhibition of DNA-binding of CTCF and thereby to
the relief of enhancer blocking [5–7,9,14–17]. Another mechanism
in the regulation of DNA binding of CTCF is in the context of
transcription, when RNA polymerase transcribes through the
CTCF binding site. This activity dislocates CTCF from the DNA
[18]. Previously, we had identified a different type of regulation of
enhancer blocking. This involves thyroid hormone (T3), which can
regulate enhancer blocking by CTCF [8]. A subset of CTCF
binding sites is found next to thyroid hormone response elements,
such asinthecompositeelements located intheratelement 144,the
mouse c-myc gene and the human APP gene. The thyroid hormone
receptor (TR) is a member of the nuclear hormone receptor family
of transcription factors. TR associates with proteins that possess
histone acetyltransferase activity (HAT) in the presence of its ligand
T3. In the absence of T3, TR is complexed with enzymes that
mediatehistone deacetylation. Forthe composite element consisting
of a CTCF and a TR binding site within the chicken lysozyme
upstream silencer, CTCF binds to footprint 1 (F1), and TR binds as
a homodimer or heterodimer with the retinoid-X-receptor (RXR)
to footprint 2 (F2). For this element it has been demonstrated that
T3 mediates relief of enhancer blocking and that activation occurs
even though CTCF remains bound to its binding site [8].
Furthermore,ChIPanalysisofthelysozymeupstreamregionrevealed
that histone H4 is acetylated at the CTCF binding site. Loss of
enhancer blocking by the addition of T3 led to increased histone
acetylation, not only at the CTCF site, but also at the enhancer and
the promoter [8]. Nuclear hormone receptor binding sites next to
important CTCF sites at the Igf2/H19 locus have been found, but
no functional effects with respect to insulation, enhancer blocking or
imprinting could be shown [19].
Here we wanted to determine whether CTCF and TR
combined sites are representative of a general feature of the
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10119genome, and whether such sites are functional in regulating
enhancer blocking.
Results
Genome wide search for binding sites for TR and for
CTCF
In order to analyze whether the occurrence of composite CTCF
and TR binding sites is a common feature for many or most CTCF
binding sites, or whether this is limited to a subset of CTCF sites, we
examined the distribution of CTCF and thyroid hormone receptor
binding elements in a genome-wide fashion. CTCF binding has
beenmappedinanumberofexperimentalapproaches.A consensus
binding sequence was derived from these studies, which was found
in a large number of the identified in vivo binding regions [20]. In
contrast to CTCF, no genome-wide binding data are available for
the thyroid hormone receptor. Nevertheless it is known that the
thyroid hormone receptor binds to DNA through conserved dimers
of the hexanucleotide sequence AGGTCA (thyroid hormone
response elements: TRE). The latter can be found in different
arrangements, such as direct repeats with 4 or 0 nucleotides spacing
(DR4 or DR0), inverted repeats spaced by 4 nucleotides (IR4) and
everted repeats with a 6 nucleotide spacing (ER6) [21]. We
constructed position specific scoring matrices (PSSM) based on half-
site models derived from the TRANSFAC-database and used the
Patsertool[22]toidentifypotentialTRbindingsitesthroughoutthe
repeat-masked human genome. Performance of our PSSM-based
approach was tested against two well-known motif prediction tools
that are especially well suited for the detection of occurrences of
nuclear hormone receptor binding sites: NHR-scan and NUBIscan
[23,24]. In order to compare the different detection methods we ran
comparisons on randomly selected 1 Mb genomic regions with the
following setting: raw score .0.7 and p,0.05 (NUBIscan), score
.6.6, p,10
213 (Patser), default parameter (NHR-scan). Despite of
the different scoring algorithms we detected identical motifs in
.80%ofthecases.Furthermorewewereableto detectanumberof
previously identified TREs such as the DR4 element in the myc N
site ([8] data notshown).To testwhether thecandidatemotifs might
be enriched in CTCF binding regions as compared to random
genomic sequences, we scanned 13720 CTCF bound regions of
1000 bp length ([20]; +/2 500 bp from annotated binding region
center) and compared them to 3500 times 13720 random genomic
controlregions. As shown in Figure 1A we could detect various half-
site arrangements in a subset of CTCF binding regions, ranging
from 2.9% (400 ER6 sites) to 8.7% (1200 DR0 sites) of the total
number of CTCF binding regions. We included the binding
sequence for Oct4/Sox2 as a control, which has been shown to
occur in functionally relevant combinations with CTCF [25], but
for which no significant correlation of CTCF and Oct4/Sox2
binding was observed [26]. Here we also find that the number of
CTCF regions with Oct4/Sox2 binding sequences is similar to
random sequences (Fig. 1A). In contrast, the occurrence of TRE
typical half site arrangements (DR4, DR0, ER6 and IR4; Fig. 1A)
was slightly increased as compared to random sequences. In order
tocontrolwhetherthisobservationindeedrepresentsanenrichment
of NR motifs next to CTCF binding sites or a bias in the underlying
base composition, we applied an additional control experiment: we
shuffled the base positions of the individual TRE motifs and used
the scrambled PSSMs to scan the 13720 CTCF binding sites. In
contrast to our previous experiment, we did not find a significantly
better performance of the realPSSM over scrambled ones (p-values:
0.17; 0.3; 0.44; 0.44 for DR4, IR4, DR0 and ER6 respectively).
Therefore we conclude that there is no significant enrichment of
TREs next to CTCF binding sites throughout the genome. This
does not rule out the principal presence of functional combinations
of CTCF/TR binding elements.
Often, several TREs occurred simultaneously in CTCF regions,
with up to three different TRE types in one CTCF region as
Figure 1. Frequency of TREs at CTCF binding regions. 13720 CTCF binding regions [20] from 2500 to +500 bp relative to the respective peak
centers were scanned with the PSSMs (DR4, DR0, IR4, ER6 and Oct4/Sox2) downloaded from TRANSFAC and Li et al. [55]. (A) Depicted is the number
of 1000 bp regions that were marked by one or more of the respective motifs (found). Those results were compared to 3500 sets of 13720 random
1000 bp sequences from the repeat masked human genome (random). Shown is the mean number of sites marked by the respective motif. To
control for potential sequence bias in the CTCF bound regions we shuffled the matrices keeping the information content constant. Shuffled matrices
were used to scan the 13720 CTCF binding sequences (yellow). Error bars indicate the maximum deviation from the mean. (B) Venn diagram
presentation of all TREs identified in CTCF regions, indicating the frequency of single, double and triple TRE occurrences at CTCF regions. (C) The
positive control for this procedure shows the highly significant detection of the CTCF consensus (found) in contrast to random sequences (random)
as in (A).
doi:10.1371/journal.pone.0010119.g001
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regions were detected that harbored at least one of the four
different TRE sequences. As a positive control for our analysis we
tested the number of cases where the CTCF consensus was found
in the CTCF binding regions (Fig. 1C). In about 70% of the
CTCF binding regions a consensus was detected, which is in
agreement with published data [20]. As expected, we found 10-
fold fewer instances in random sequences or using the scrambled
versions of CTCF PSSM (Fig. 1C).
Taken together these data indicate that TR binding motifs mark
a fraction of CTCF binding regions. The frequency of composite
CTCF/TR elements is not higher than that detected with
scrambled PSSMs. This finding does not support a general role
for the TR. Despite of this, individual composite elements could be
functional as exemplified with the CTCF/Oct4/Sox2 cases
[25,26]. From these data we reasoned that although individual
examples for composite CTCT/TR binding elements are not a
general feature of CTCF binding regions, a number of functional
TRE motifs in the vicinity of CTCF binding sites might exist.
In order to functionally verify the predicted composite CTCF/
TR binding sites, we concentrated on those genes which have been
shown to be regulated by T3 in the mouse or in the rat [27–30]
(Fig. 2A). From these we screened 94 genes conserved in human
for the presence of a CTCF binding site (CTS) within or outside of
the transcribed region including 40 kb of flanking sequence
upstream and downstream. For CTCF we again used the dataset
of genome wide CTCF binding [20]. We identified 31 T3
responsive genes with one or more CTCF binding sites, whereas
63 did not contain a known CTCF target site. In order to predict
TR binding sites within the T3 responsive genes we used the
NubiScan algorithm, which allows the prediction of nuclear
receptor response elements [23]. We focused on the direct repeats
DR0 and DR4, as well as on the palindromes IR4 and ER6, which
are known to bind either TR homo or TR/RXR heterodimers
[21]. We divided each of the gene loci into the 59region and the
intronic plus 39region. Of the 31 gene loci with a CTCF site, 23
harbor CTCF sites in the 59region. For these a TR binding site in
a range of +/2 1 kb flanking a CTS could be identified in 13
cases. Within the intronic and 39 CTS group, TREs could be
identified in the vicinity of a CTS in 4 cases. Thus, a total of 17
gene loci harbor a composite TRE/CTS. Based on the score of
binding site predictions, we chose 10 (Fig. 2) for experimental
analysis.
Composite elements are bound by TR and CTCF
In vivo binding of CTCF to the gene regions shown in Figure 2
has been documented by genome wide binding analysis [20]. The
in vivo response to T3 for the selected genes has been shown as
well [27–30]. In order to identify the precise binding sites and to
validate the TRE predictions, we tested TR and CTCF binding in
vitro using the electrophoretic mobility shift assay (EMSA). For
CTCF analysis we used a fusion of GST with the zinc finger
domain of CTCF (GST-CTCF-ZF) expressed in E.coli. The DNA
probes were selected by CTCF binding site prediction for each of
the 10 genes chosen (Fig. 2B). In all cases, GST-CTCF-ZF resulted
in a retarded band (Fig. 3A). For the Catechol-o-methyl-transferase
gene (COMT) two CTS are predicted at the downstream
promoter, both of which are bound as well. The bound complex
could be competed by an unrelated CTCF binding site (F1),
whereas the negative control, GST protein expressed in E.coli,
resulted in no specifically retarded complex.
In order to confirm that these CTS elements are indeed the
same sequences identified by genome wide CTCF binding
analyses [20,31], we precipitated HeLa cell chromatin with an
antibody directed against CTCF. Exemplarily, we analyzed the
precipitate for the presence of five of the sequences shifted by
CTCF and found all to be bound in vivo as well (Fig. S1).
Figure 2. Schematic representation of genes with a composite
element. (A) 94 T3 responsive genes conserved in mice and man
searched for CTCF composite elements (see main text). (B) Each
diagram presents a region of the indicated gene. Putative binding sites
for CTCF (CTS), binding sites for TR (IR4, DR4, DR5, ER6 or DR0) and the
transcriptional start site (arrow) are shown. Elements being shown to
bind TR or CTCF (see Fig. 3) are indicated in green.
doi:10.1371/journal.pone.0010119.g002
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predicted binding sites of these T3 responsive genes. Binding site
prediction in several cases identified two or more potential TRE
elements. These have half site arrangements of the type DR0,
DR4, IR4, ER6 or an atypical [32] DR5 site (Fig. 2B). The DR4
element shows a clear shift in mobility when incubated with GST-
TR at the COMT downstream promoter, but is not shifted with
GST alone (Fig. 3B). The binding is specific as competition by a
known TR binding site (F2) abolished protein binding, and
competition with a mutated F2 site did not (Fig. S2). No shift is
visible when the IR4 element of the COMT gene is incubated with
GST-TR, indicating that this sequence is not bound by TR in
vitro (Fig. 3B).
We examined all predicted TR binding sites and could identify
several new TR target sites. A detailed summary of these results is
shown in Table 1 and the confirmed binding sites are indicated by
green lettering (Fig. 2B). In general, all of these 10 identified
regions at T3 responsive genes harbor a functional TR binding
element, validating the PSSM procedure to predict TR binding
sites as described above. Chromatin precipitation for TR could not
Figure 3. In vitro binding assays (EMSA) show direct binding of CTCF and TRb to predicted target sites. EMSA experiments were
performed using E.coli expressed GST, GST-CTCF-ZF (A) or GST-TR (B) with the indicated radioactively labeled probes. For competition experiments a
50-fold molar excess of non-labeled probes were used. These were either an unrelated CTCF binding site (F1) or an unrelated TR binding site (F2).
Arrows mark the CTCF or TR specific shift.
doi:10.1371/journal.pone.0010119.g003
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products are involved in neurotransmission, physiology, signalling,
transcriptional regulation and cell cycle. Four genes are up-
regulated and six are down-regulated by T3. CTCF knockdown
[33] affects three of these genes, with two of them being repressed
and one being induced (Table 1).
Hormone sensitive enhancer blocking on episomes
In order to functionally analyze hormone regulated enhancer
blocking, we used a test system based on episomal vectors. The
episomal system has the advantage that the reporter DNA is not
integrated into the genome, and furthermore that the DNA is
packaged into chromatin [34]. Therefore, this system allows the
study of transcriptional regulation on properly formed chromatin
independent of the integration locus in the genome. Using stably
integrated DNA for the CTCF/TR composite element of the
chicken lysozyme gene (F1F2 element), we have previously shown
that CTCF mediated enhancer blocking is T3 sensitive [8]. We
wondered whether we could use the F1F2 element as a crucial test
system to study composite CTCF/TR elements with episomes.
Enhancer function and enhancer blocking is quantified by
measuring the activity of the luciferase reporter gene. Transfection
of a series of episomes into N2ab cells, which express TRb,
revealed that F1F2 mediates enhancer blocking, which is
dependent on both the presence of the F1F2 element and
enhancer (Fig. 4A, B). A single F1F2 element mediates weak
enhancer blocking, whereas a five times multimerized element
(5xF1F2) mediates a more than five-fold robust enhancer blocking.
The backbone vectors pR or pR E do not change the luciferase
activity after the addition of thyroid hormone, whereas in contrast
the pR F1F2 E or pR 5xF1F2 E constructs fully abolish enhancer
blocking. Again, this effect depends on the presence of the
enhancer, since the enhancer-less constructs show only a weak T3
response.
It is known that the CTCF-mediated repression function is
partially sensitive to the HDAC-inhibitor Trichostatin A (TSA)
[35]. Furthermore, it has been shown that CTCF is able to recruit
HDAC activity from HeLa extract and interacts in vitro with
Sin3A [35]. We analyzed whether TSA has an influence not only
on repression, but also on the enhancer blocking function of
CTCF. Incubation of the cells transfected with the enhancer
blocking F1F2 episome with TSA resulted in a reduction of
enhancer blocking activity to about 25% as compared to untreated
cells (Fig. 4C). This indicates that HDACs are not only involved in
the repression function of CTCF, but also in enhancer blocking.
Another modification of CTCF, poly (ADP)-ribose (PAR)
binding, has been shown to be essential for mediating enhancer
blocking and insulation [36,37]. If indeed the episomal enhancer
Table 1. Ten T3 regulated genes harbor CTCF/TR composite elements.
Name Characteristics Function Regulation Ref.
COMT Catechol-O-methyltransferase is found in
two forms, a soluble form (S-COMT) and a
membrane-bound form (MB-COMT).
COMT catalyzes the transfer of a methyl group from
S-adenosylmethionine to catecholamines, including
the neurotransmitters dopamine, epinephrine, and
norepinephrine.
Down regulated upon T3
treatment.
[29]
SCD Four Stearoyl-CoA desaturase isoforms, Scd1
through Scd4, have been identified in
mouse. 2 SCD isoforms, SCD1 and SCD5,
have been identified in human.
SCD is an iron-containing enzyme that catalyzes a
rate-limiting step in the synthesis of unsaturated fatty
acids.
Up regulated upon T3
treatment.
[29]
PTPRF Protein tyrosine phosphatase receptor type
F possesses an extracellular region, a
transmembrane region, and two tandem
intracytoplasmic catalytic domains.
PTPs are signaling molecules that regulate a variety of
cellular processes including cell growth, differentiation,
mitotic cycle, and oncogenic transformation.
Up regulated upon T3
treatment.
[27]
NR2F1 Nuclear receptor subfamily 2, group F
(COUP-TF) is a nuclear receptor and binds
to both direct repeats and palindromes of
the 59-AGGTCA-39 motif.
NR2F1 transcription factor binds to the ovalbumin
promoter and, in conjunction with another protein
(S300-II) stimulates initiation of transcription.
Down regulated upon T3
treatment. Slightly induced
after CTCF knockdown.
[27,33]
ESRRA Estrogen-related receptor alpha is a nuclear
receptor that is closely related to the
estrogen receptor.
ESRRa function has been demonstrated in the regulation
of a variety of genes including lactoferrin, osteopontin,
medium-chain acyl coenzyme A dehydrogenase (MCAD)
and thyroid hormone receptor genes.
Down regulated upon T3
treatment.
[27]
PER1 Period1 is expressed in a circadian pattern
in the suprachiasmatic nucleus, the primary
circadian pacemaker in the mammalian brain.
PER1 Influences clock function by interacting with other
circadian regulatory proteins and transporting them to
the nucleus.
Down regulated upon T3
treatment.
[29]
LRP1 Low density lipoprotein-related protein 1 is
required for early embryonic development
and involved in cellular lipid homeostasis.
LRP1 is an endocytic receptor involved in endocytosis
and in phagocytosis of apoptotic cells.
Down regulated upon T3
treatment.
[28]
BCL3 B-cell lymphoma 3 is a proto-oncogene
candidate translocated into the immunoglobulin
alpha-locus in some cases of B-cell leukemia.
BCL3 could be a transcriptional activating factor. Inhibits
translocation of NF-kappa-B p50 subunit to the nucleus.
Up regulated upon T3
treatment. Repressed after
CTCF knockdown.
[28,33]
PCK1 Phosphoenolpyruvate carboxykinase 1 is
a main control point for the regulation of
gluconeogenesis.
PCK1, along with GTP, catalyzes the formation of
phosphoenolpyruvate from oxaloacetate, with the
release of carbon dioxide and GDP.
Up regulated upon T3
treatment.
[30]
LMNA Lamin A is a family member of matrix
proteins that are highly conserved in
evolution.
During mitosis, the lamina matrix is reversibly
disassembled as the lamin proteins are phosphorylated.
Lamin proteins are thought to be involved in nuclear
stability, chromatin structure and gene expression.
Down regulated upon T3
treatment. Slightly repressed
upon CTCF knockdown.
[28,33]
doi:10.1371/journal.pone.0010119.t001
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PLoS ONE | www.plosone.org 5 April 2010 | Volume 5 | Issue 4 | e10119Figure 4. F1F2 and ESRRa composite elements mediate hormone sensitive enhancer blocking on episomes. (A) Schematic
representation of the insulator-enhancer-reporter arrangement of the episomal vectors. The composite insulator sequence (CTCF/TR) is usually
integrated as a single insert, or as 4x or 5x multimers as indicated for the constructs used. Cells transfected with the indicated episomes were
incubated for 48 h in the absence or presence of T3. (B) Efficient enhancer blocking depends on the presence of the enhancer. The repressive effects
cannot be attributed to direct promoter repression. Transfection was in N2ab cells. (C) TSA and 3-ABA were added 8 h or 28 h after transfection,
respectively. Transfection was in N2ab cells. (D–F) HepG2 cells were additionally cotransfected with 0.2 mgT R b expression vector. (F) Comparison of
the enhancer-less constructs with the enhancer constructs demonstrate that the enhancer blocking activity is dependent on the enhancer.
doi:10.1371/journal.pone.0010119.g004
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endogenous genomic insulators, PAR modification should affect
the episomal assay. Therefore we used the inhibitor of PAR
polymerases, 3-Aminobenzamide (3-ABA), for the transfection
experiments. The CTCF-mediated enhancer blocking is decreased
to about 70% upon the addition of 3-ABA (Fig. 4C).
Thus, the episomal system used in these experiments fully
mimics the enhancer blocking function of insulators integrated in
the genome.
T3 responsive and non-responsive composite CTS
elements
Since the episomal system proved to be suitable for the analysis
of composite CTCF/TR binding sites, we generated enhancer
blocking episomes with the newly identified composite elements.
HepG2 cells were chosen as a test system because most T3
responsive genes found are expressed in liver. Single insertions of
LMNA, PCK1, ESSRA, COMT, NR2F1, BCL3 and PTPRF
mediated weak enhancer blocking (Fig. 4D). The arrangement of
the LMNA composite element relative to the promoter is, in
contrast to the other genes, downstream of the promoter.
Therefore, we also tested the antisense orientation in the episome
(pR LMNA(as) E), which did not show any enhancer blocking
activity. Two of the elements, the positive control F1F2 and
ESRRA, mediated enhancer blocking in the absence of T3,
whereas T3 fully abolished this activity. In order to detect possible
weak effects in enhancer blocking and T3 mediated relief from
enhancer blocking, we generated four or five times multimerized
composite CTCF/TR binding sites. In six cases, F1F2, ESRRA,
COMT, NR2F1, BCL3 and PTPRF a significant increase in
enhancer blocking activity could be seen (Fig. 4E). In contrast to
these new enhancer blocking elements, the composite CTS of
LRP1 and LMNA in either orientation did not confer enhancer
blocking. In all cases we challenged the luciferase activity by
incubation with T3. The composite elements of PCK1, COMT,
NR2F1, BCL3 and PTPRF mediated constitutive enhancer
blocking, which could not be relieved by T3 (Fig. 4D, E). In
contrast, the ESRRA element as a single insertion or when
multimerized four times resulted in a T3 mediated complete
release of enhancer blocking (Fig. 4D, E). We could not detect any
repressive/silencing effects of the ESRRA element on the
luciferase promoter using the enhancer-less episomal vectors
(Fig. 4F). Thus, the effects seen are dependent on an enhancer
and can therefore be defined as enhancer blocking.
Taken together the ESRRA element is a new composite
element mediating hormone sensitive enhancer blocking and
together with the F1F2 element is suitable for further studies.
Functional CTS composite elements depend on both, TR
and CTCF
Since T3 relieves the enhancer blocking activity from the F1F2
and the ESRRA composite elements, we wanted to address a
possible contribution of the TR to enhancer blocking in the
absence of T3. As a control we tested the contribution of CTCF to
enhancer blocking by utilizing 293T cells, which allow for high
level expression. Since CTCF is expressed in all cell types, we used
transfection conditions resulting in a low level of enhancer
blocking. Co-transfection of an expression vector for CTCF leads
to a significant increase in enhancer blocking on the F1F2 and
ESRRA elements, indicating that CTCF is at least contributing to
enhancer blocking (Fig. 5A). In a complementary approach we
reduced the amount of CTCF using a tetracycline inducible
shRNA-mediated knock-down of CTCF. After 48 hours this
antisense approach resulted in a down regulation of CTCF protein
to about 50% (Fig. S3). This decreased expression of CTCF led to
a 50% decrease in enhancer blocking (Fig. 5B), again confirming
that CTCF is involved in the observed enhancer blocking. The
addition of T3 completely abolishes enhancer blocking both when
the blocking is increased after CTCF overexpression, and is
decreased after CTCF knockdown.
We then tested the influence of TR on enhancer blocking. We
transfected F1F2-containing episomes into N2a cells, that is a cell
line which, in contrast to N2ab cells, does not express TR. This
allows for the testing of TR mediated effects upon TR expression.
We observed that CTCF alone is not sufficient to mediate
enhancer blocking, whereas the cotransfection of a TR expression
vector restores enhancer blocking (Fig. 5C). The same is true for
the ESRRA element containing episomes when transfected into
HepG2 cells. These cells have a reduced amount of TR resulting
in a reduced T3 induction of transfected DR4 luc reporter DNA.
Full DR4 reporter activity can only be achieved upon overex-
pression of TRb (data not shown). Therefore, we cotransfected the
TRb expression vector and the episomal reporter construct. This
resulted in about a 5-fold enhancer blocking using the ESRRA or
the F1F2 elements (Fig. 5C). Likewise, the enhancer blocking
activity of both elements, F1F2 and ESRRA, was dependent on
the expression of TRb when using 293T recipient cells.
This strong impact of the unliganded TR on enhancer blocking
was unexpected. Therefore we wanted to understand the
individual contribution of CTCF and TR to enhancer blocking
and mutated the individual binding sites within the F1F2 element.
To abolish CTCF binding to its cognate binding site, 2 nucleotides
within the F1 binding site of CTCF were changed (AA – GG) and
tested in band shift assays using E.coli expressed CTCF-zinc finger
domain fused to GST (GST-CTCF ZF). The F1wt binding site is
shifted by GST-CTCF ZF. This shift can be competed with an
excess of unlabelled F1wt site but not by the same excess of
unlabelled mutated F1 site (Fig. 5D). To test the functional
consequence on enhancer blocking by the mutated binding site,
we performed transfection experiments with episomes containing
the F1F2 or the F1mutF2 binding sites. These experiments
revealed that in contrast to the wt F1F2 element, the F1mutF2
binding site is not capable of mediating significant enhancer
blocking (Fig. 5E).
To test the effects of TR on CTCF mediated enhancer blocking,
we mutated the two half sites of the F2 element, which is
characterized by an everted palindrome spaced by 6 nucleotides.
We performed band shift assays with the wt F2 sequence as a
probe, and bound GST-TR could be fully competed by the
addition of unlabelled wild type probe. In contrast, the mutated
unlabelled F2 element could not compete this shift even at a high
molar excess (Fig. 5D). To test the functional consequences of the
mutated F2 in enhancer blocking we introduced this mutation into
the F1F2 enhancer blocking construct. Transfection experiments
with constructs containing F1F2wt or F1F2mut showed that
mutation of the F2 binding site did not only abrogate any T3
effect, but also impaired enhancer blocking (Fig. 5E).
These results demonstrate that enhancer blocking depends on
the presence of two factors, CTCF and TR. CTCF alone is not
able to mediate enhancer blocking on these composite elements,
an unliganded TR synergizes with CTCF and this synergism can
then be abolished by the presence of T3.
TR interaction with CTCF has been shown [38]. The
physiological TR/DNA complex may be a TR homodimer or a
TR and RXR heterodimer [21]. Therefore we tested whether
CTCF interacts with TR, RXR, or with both. We performed GST
pull-down assays with GST fused CTCF and
35S-radiolabeled TR
Composite CTCF Binding Sites
PLoS ONE | www.plosone.org 7 April 2010 | Volume 5 | Issue 4 | e10119Figure 5. CTCF and TR synergize in enhancer blocking. Cells transfected with episomes were incubated for 48 h in the absence or presence of
T3. ESRRA = abbr. ERR. (A) 293T cells were transfected with the indicated episomes, a TRb expression vector, and with either the CTCF expression
vector (CTCF) or an empty vector (vector). (B) A 293T cell clone containing a stably integrated vector with Tet-inducible expression of shRNA against
CTCF was transfected with the indicated reporter episome and the TRb expression vector. The cells were incubated with tetracycline for 0, 24 or 48 h.
(C) Indicated cell lines expressing either a low amount of or no TRb were transfected with reporter episomes and either empty vector (vector) or TRb-
expression (TRb). (D) EMSA experiments were performed using E.coli expressed GST, GST-CTCF-ZF and GST-TR and radioactively labeled F1/F2 probe.
For competition experiments, non-labeled probes (N) were used in amounts as indicated. (E) Either the mutated F1 (F1mutF2) or the mutated F2
(F1F2mut) were tested in N2a cells in the presence of TR-expression vector.
doi:10.1371/journal.pone.0010119.g005
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and RXR interact with CTCF (Fig. 6A). To identify domains of
the receptor required for interaction we generated GST fusions
with the individual DNA binding domains (DBD) of TR and RXR
or with the ligand binding domain (LBD). The TR-DBD binds
very efficiently and seems to harbor the main interaction interface.
The N-terminal domain of RXR binds to CTCF to a lesser
extent,the ligand binding domain shows no CTCF binding in the
case of RXR, and only weak binding in the case of TR (Fig. 6A).
Thus the DBD of TR harbors two potentially important
functions for enhancer blocking, such as DNA binding and an
interface for the physical interaction with CTCF. Therefore we
functionally tested the TR-DBD for enhancer blocking. We used
cells that do not express endogenous TR (N2a cells) and expressed
either full length TR or the DNA binding domain of TR. In
contrast to the TR-DBD, only full length TR results in strong
enhancer blocking of the F1F2 episome (Fig. 6B). This indicates
that the TR-DBD is not sufficient for enhancer blocking and that
other domains outside the DNA binding domain of TR are needed
as well to mediate enhancer blocking of the CTCF bound module
and the unliganded TR.
Discussion
CTCF binding sites have been found next to thyroid or steroid
receptor bindingsites inseveralcases [8,39,40].Fora subset of these
sites we could demonstrate that enhancer blocking is regulated by
thyroid hormone [8]. In other cases, clustered binding sites for
steroid receptors next to highly conserved CTCF sites in the Igf2/
H19 locus, a function could not be demonstrated [19]. Therefore,
we wanted to know the frequency of combined binding sites for
CTCF and the thyroid hormone receptor in the genome.
Of 13720 CTCF bound regions we found about 18% to harbor
a potential TRE. This ratio is slightly higher than random
sequences associated with CTCF bound regions. Clearly, the
positive control to search for the CTCF consensus within these
regions revealed a significant 22 fold higher frequency as
compared to random controls. We checked the PSSMs for
different half-site models against whole genome datasets of the
estrogen receptor (ER) and the retinoic acid receptor alpha
(RARa) [40,41] in order to validate our approach in identifying
such elements next to CTCF sites. In these calculations we found
that the respective half-site models (IR3 and DR5) showed no
significant enrichment when we compared the genome-wide
binding datasets with control sequences (data not shown).
Previous analysis of estrogen receptor binding sites in compar-
ison with CTCF binding revealed that CTCF site distribution
strongly correlated with gene density in contrast to ER sites [20].
Based on the CTCF distribution, the genome can be dissected into
sequence blocks framed by CTCF sites. About 3000 such CTCF
blocks have been found to contain ER binding sites [42]. The
authors concluded that CTCF confines the distal action of the
estrogen receptor. This would argue for a clear separation of
CTCF and ER sites in function and space for most of the binding
sites. This is in line with the finding that of 1600 ER sites analyzed,
about 100 colocalized with the CTCF motif [40]. Overall, the
ratio of composite CTCF and TR binding sites relative to the total
number of TR or CTCF sites is within the same magnitude as
found for ER and CTCF.
Despite the low frequency of composite CTCF/TR binding
elements, these can be important and functional. The importance
of low frequency composite elements has been illustrated by the
recent finding that binding of Oct4 and CTCF to a composite
element of the Xist gene is required for the regulation of X
chromosome inactivation [25] (Fig. 7). Nevertheless, there is no
overall correlation of combined binding of CTCF and Oct4 in the
genome [26]. Likewise, we do not observe an enrichment of the
Oct4 motif in the vicinity of CTCF binding regions as compared
to random genomic regions (see Fig. 1A).
For the functional characterization of the TR/CTCF composite
elements we used the episomal system. Episomal constructs are
able to mimic endogenous chromatin and can be used for insulator
analysis [43–46]. We found that for the episomal vectors that we
constructed, the analysis of enhancer blocking is also possible.
Addition of T3 relieves enhancer blocking, an important control
that demonstrates that the episomal system can be used to study
T3 regulated enhancer blocking. Thereby we identified a new
composite element at the ESRRA gene, which indeed mediates T3
regulation of enhancer blocking. Furthermore, CTCF and
Figure 6. TR requires more than just the CTCF interaction domain to mediate enhancer blocking. (A) GST-pulldown experiments were
carried out using the indicated E.coli expressed GST-fusion proteins. (B) N2a cells were transfected with the indicated episomes and expression vector
for full length TRb or for TRb DBD and incubated in the absence or presence of T3.
doi:10.1371/journal.pone.0010119.g006
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system as has been demonstrated for endogenous genes. Both the
enhancer blocking activity of CTCF as well as the transcriptional
repression of rDNA genes by CTCF require poly(ADP)ribosyla-
tion [36,47]. Tumor suppressor silencing has been recently shown
to be caused by a deficiency in poly(ADP)ribosylation [37]. In line
with these results we could demonstrate that episomal enhancer
blocking mediated by a composite binding site is sensitive to a
poly(ADP)ribosylation inhibitor as well. Furthermore, changes in
histone acetylation in the context of enhancer blocking or
insulation have been shown. For CTCF binding sites, an increase
in acetylation of histone H3 as well as of H4 has been reported
[48,49]. In contrast, CTCF binding to histone deacetylase activity
has been found as well [35], and functional episomal tests of the b
globin insulator demonstrated a general histone deacetylation in
the region extending from the enhancer to the gene [43].
Why is the ESRRA gene down-regulated after T3 treatment,
whereas the assay shown above indicates a loss of enhancer
blocking by T3? We can only speculate that from the different
promoters of the gene one may be induced, which may cause other
promoters to be turned of.
This assay revealed for the first time that in the case of two
composite elements a functional synergy between CTCF and the
unliganded TR confers enhancer blocking. This shows that,
similar to enhancer elements which are comprised of functional
modules (binding sites for enhancer factors), enhancer blockers are
generated from functional and synergizing modules as well (Fig. 7).
Again, in analogy to enhancer elements, functional modules can
be multimers of identical factors (CTCF) as in the case of the H19
locus [50,51] or in the X inactivation locus of the active
mammalian X chromosome [15], or different factors such as
combinations of CTCF with Oct4 [25], Kaiso [52], Yy1 [53] or
TR, as shown here. In these cases (Fig. 7), binding of both factors
involved is required to mediate the biological function.
Materials and Methods
Motif scanning
Half site models for nuclear receptor were downloaded from
TRANSFAC database. Next we built PSSMs with the appropriate
spacing (ER6, DR4, DR0, IR4). The PSSM for CTCF was derived
from published genomewide CTCF binding data [20] by scanning
the top 1000 binding regions with the MEME tool [54]. The PSSM
for the combined Oct4/Sox2 sites was taken from Li et al. [55].
PSSMs were used to scan 13720 described CTCF binding regions
from 2500 bp to +500 bp relative to individual peak centers using
the Patser tool of the RSAT suite [22]. In case of the NR half site
modelswe compared the performance of our prediction method with
the NHR-Scan and NUBIscan tools [23,24] on random 1 Mb
regions and found identical motif prediction in .80% of the cases.
Random control datasets were generated with custom BioPerl scripts
from the repeat masked human genome downloaded from UCSC
(http://hgdownload.cse.ucsc.edu/goldenPath/hg18/bigZips/). 2000
repetitions of such control experiments were conducted. To control
for biases in the sequence composition of the CTCF binding regions
w es h u f f le dt h eb a s ep o si t i o n so ft h eP S SM sa n du s e dt h e s et osc a nt h e
13720 CTCF binding regions. In case of the NR half sites models we
tested all possible permutations (720) using the same permutation in
both half sites. For the CTCF and Oct4/Sox2 PSSMs we tested the
same number of random permutations. Empirical p-values were
calculated as the fraction of simulations that produced a number of
mapped features as extreme as observed in the real data [56].
Plasmid construction
A second MCS (PstI, EcoRI, BglII, EcoRV, Spe) was inserted into
the ClaI site of the pGL3-control vector (Promega). pR-E was
generated by digesting the pGL3-MCSII vector with BamHI fill in
and NheI and cloned in NotI fill in and NheI cut pREP4-ss. pREP4-
ss is a pREP4 vector (Invitrogen), where the RSV LTR promoter was
removed. The F1F2 element of the chicken lysozyme gene was
amplifiedwithprimerpairscontainingSpeIandBglIIrestrictionsites.
The PCR product was cloned into the BglII and SpeI sites of the
MCSII of the pGL3-MCSII vector generating pGL3F1F2. pRF1F2E
was generated by digesting the pGL3F1F2 vector with BamHI and
XhoI, and was cloned blunt end into pREP4-ss NotI blunt ended.
The F1F2 element was multimerized by ligating PCR products
amplified from the pGL3F1F2 vector with primers containing SpeI
and XbaI restriction sites. The 5xF1F2 was subcloned blunt into
pBK-CMV (pBK-CMV5xF1F2), further cloned as a XbaI and
B a m H 1f r a g m e n ti n t op G L 3 - M C S I Id i g e s t e dw i t hS p e Ia n dB g l I I
(pGL3-5xF1F2) and again cloned as a BamH1/XhoI fragment into
pREP4-ss NotI blunt to generate pR5xF1F2E. pRF1mutF2E was
generated as follows: Primer containing the F1mut binding site were
annealed and directly cloned into the XbaI, HindIII site of pBK-
CMV (Stratagene). Primer containing the F2 element were annealed
and directly cloned into the HindIII, BamHI site of pBK-CMV
F1mut. pGL3F1mutF2 was generated by digested pBK-
CMVF1mutF2 with XbaI and SpeI and cloning the fragment into
the SpeI site of pGL3-MCSII. pRF1mutF2E was generated by
digesting pGL3-F1mutF2 with SalI fill in and NheI and cloned into
pREP4-ss cut with NotI fill in and NheI. pRF1F2mutE was cloned in
the same manner with F1 and F2mut oligos.
pRCOMTE was generated by PCR amplification of the
genomic locus with corresponding primer pairs containing SpeI
and XbaI restriction sites and subcloned into pBSK (Stratagene)
generating pBSK-COMT. To multimerize binding sites pBSK-
Figure 7. Modular CTCF binding sites. Enhancer blocking elements
may require multiple CTCF sites for optimal function, as exemplified at
the H19 locus or the Xist and Tsix locus [15,50,51] (top). The composite
elements of the lysozyme and ESRRA genes require binding of RXR and/
or TR for enhancer blocking (second row). Long range chromatin
interaction is not only required for enhancer blocking, but for X
chromosomal pairing and HLA locus interaction as well. In addition to
CTCF, this involves Yy1 and Oct4 [25,53,62] (third row) or CIITA at the
CTCF site and RFX at the interacting site [63,64] (bottom row).
doi:10.1371/journal.pone.0010119.g007
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COMT cut with XbaI and NotI. pBSK-COMT was digested with
with XbaI and SpeI and cloned into pGL3-MCSII digested with
SpeI to generate pGL3-COMT and again cloned as a BamH1 fill
in NheI fragment into pREP4-ss digested with NotI fill in and
NheI. All other newly identified CTCF and TR binding sites were
cloned in the same manner. To generate enhancer-less episomes
the corresponding pGL3-vector was cut with EcoRV and NheI
and cloned into pREP4-ss digested with NotI fill in and NheI.
Cell culture and transfection
The clonal cell line Neuro-2a stably transfected with the b1
isoform of the human thyroid hormone receptor [57] (N2a-b cells),
HepG2 (ATCC HB-8065
TM) and HEK293T (ATCC CRL-
11268
TM) were grown in Dulbecco’s modified Eagle’s medium
supplemented with 10% (v/v) charcoal stripped hormone-depleted
serum and 1% PenStrep.
N2ab and 293T cells were transfected using the calcium
phosphate method essentially as described [58]. In detail, cells
were transfected with 1 mg reporter plasmid per 6-well dish or as
indicated. 24 h after transfection T3 (10
26 M) was added to the
medium for 48 h before harvesting cells.
For TSA experiments, TSA (BIOMOL) was added 8 h after
transfection at a concentration of 10 ng/ml. Cells were harvested
after 40 h of TSA treatment.
3-ABA (Sigma) was added 28 h after transfection at a final
concentration of 8 mM. and cells were collected 14 h later.
Electrophoretic mobility shift assay
Radiolabeled DNA probes (Table S1) were generated by
phosphorylation with gamma
32P ATP and subsequently an-
nealed. The probes were incubated with 0.5–2 mg of purified
GST, GST-CTCF-ZF and human GST-TR. Recombinant
proteins were prepared as described previously [59]. The binding
reaction was performed in PBS ([pH 7.4], supplemented with
5 mM MgCl2, 1 mM ZnCl2, 1 mM DTT, 0.1% NP-40 and 10%
glycerol) for 20 min at room temperature in the presence of
200 ng/ml pdIdC and 25–100 ng/ml salmon sperm DNA. Protein-
DNA complexes were analyzed on nondenaturing polyacrylamide
gels (5% acrylamide [w/v]) in TAE-buffer. Electrophoresis was
performed at 4uC with a field strength of 12 V/cm for 3–4 h.
Chromatin immunoprecipitation
ChIP assays were performed as previously described [60] with
following modifications: 1610
7 HeLa-cells (ATCC CCL-2
TM)i n
1 ml SDS lysis buffer were sonicated 7 times on ice with a Branson
250 sonifier on setting 1, constant for 10 secs to an average length
of approximately 300–800 bp. Sonicated chromatin from 2610
6
cells was diluted 10-fold in ChIP dilution buffer and precleared
with 30 ml of salmon sperm DNA/protein A agarose solution
(Santa Cruz #16-157) and 5 mg preimmune serum for 2 hrs
before overnight incubation at 4uC with antibody or controls.
For immunoprecipitation we used antibodies specific for CTCF
[61] and preimmune serum. Gene specific PCR mixtures
contained 1 ml of DNA, 0.5 mM of each primer (Table S1);
1.5 mM MgCl2, 0.2 mM dNTPs, and 1.25 U of Taq DNA
polymerase (Panscript) in a total volume of 35 ml. Following 32 to
37 cycles of amplification, PCR products were run on a 3%
agarose gel and analyzed by ethidium bromide staining. Annealing
temperatures and cycling conditions were determined empirically
for each primer set.
GST-pulldown
GST and GST fusion proteins were expressed in Escherichia coli
BL21. Bacteria were induced with 0.5 mM isopropyl-D-thiogalac-
topyranoside for 5 h at RT. Recombinant proteins were purified
with glutathione–sepharose beads (Amersham Pharmacia Biotech
AB) and analyzed on SDS–PAGE to normalize protein amounts
(Fig. S4). Equivalent amounts of GST fusion proteins were
incubated with [35S]methionine-labeled proteins, produced by the
T7\T3 TNT-coupled transcription/translation system (Promega)
in 200 ml of binding buffer. After 2 h incubation at 4uC the beads
were washed 3 times with 1 ml of binding buffer without BSA.
The bound proteins were eluted with SDS sample buffer,
fractionated on SDS–PAGE visualized by fluorography.
Supporting Information
Figure S1 ChIP-assay demonstrates in vivo binding of CTCF.
ChIP was performed using chromatin from HeLa cells and
immunoprecipitated using antibodies against CTCF. Specific
primers (see Table S1) for the CTCF target sites (CTS) were used
in the PCR-reaction. Negative controls: nonspecific antibody
(IGG) and a nonbinding sequence (ESRRa-control).
Found at: doi:10.1371/journal.pone.0010119.s001 (0.26 MB TIF)
Figure S2 Specificity of in vitro binding of TRb to predicted
target sites. EMSA experiments were performed using E.coli
expressed GST and GST-TR with the indicated radioactively
labeled probe. For competition experiments a 0.5 or 50-fold molar
excess of non-labeled TR binding site (F2) or unspecific probe (N)
were used. Arrow marks the TR specific shift.
Found at: doi:10.1371/journal.pone.0010119.s002 (0.24 MB TIF)
Figure S3 Tetracycline inducible shRNA-mediated knock-down
of CTCF. Protein levels were measured by western blotting using
an anti-CTCF antibody or GAPDH as control. 293T cells of each
transfected sample (see Fig. 5B) were collected and analyzed by
7.5% SDS PAGE. The CTCF knockdown results in a reduction of
about 50%.
Found at: doi:10.1371/journal.pone.0010119.s003 (0.25 MB TIF)
Figure S4 Coomassie stained gel shows expression levels of
GST-fusion proteins. Asterisks mark the corresponding GST-
fusion proteins.
Found at: doi:10.1371/journal.pone.0010119.s004 (0.75 MB TIF)
Table S1 List of oligonucleotides used in different applications.
Found at: doi:10.1371/journal.pone.0010119.s005 (0.12 MB
DOC)
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